Search

Zentalis Pharmaceuticals Inc

Slēgts

3.82

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.8

Max

3.85

Galvenie mērījumi

By Trading Economics

Ienākumi

-42M

-78M

EPS

-0.59

Darbinieki

106

EBITDA

-42M

-77M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+131.15% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 6. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

20M

351M

Iepriekšējā atvēršanas cena

3.82

Iepriekšējā slēgšanas cena

3.82

Zentalis Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 22. aug. 23:51 UTC

RBA Meeting Minutes Release on August 25, 2026, Sparks Cautious Market Sentiment Amid Persistent Inflation and Economic Cooling in Australia.

2026. g. 22. aug. 23:51 UTC

Macro News

Bitcoin is trading lower during Saturday's session, despite earlier rising above $70,000, amid ongoing geopolitical tensions and pressures in the bond market.

2026. g. 22. aug. 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields raise concerns over economic growth and investor sentiment shifts towards safer assets.

2026. g. 22. aug. 23:41 UTC

Cryptocurrency Prices Drop Amid Rising Bond Yields and Geopolitical Tensions, Impacting Market Sentiment.

2026. g. 22. aug. 23:41 UTC

Cryptocurrency Markets Decline Amid Rising Bond Yields and Economic Pressures, with Ethereum Down 3.9% and Bitcoin 1.7%.

2026. g. 22. aug. 23:41 UTC

Bitcoin and Ethereum decline as rising bond yields and inflation concerns pressure risk assets amid mixed global market performance.

2026. g. 22. aug. 23:41 UTC

U.S. Goods Trade Balance Expected to Show $99 Billion Deficit Amidst Rising Tariff Tensions with Canada

2026. g. 22. aug. 23:41 UTC

Upcoming U.S. Retail Inventories Ex Autos Data Release on August 27, 2026, Expected to Impact Market Sentiment Amid Cautious Investor Outlook.

2026. g. 22. aug. 23:41 UTC

U.S. Wholesale Inventories Expected to Rise 0.1% Amid Caution Over Economic Conditions and Market Volatility

2026. g. 22. aug. 23:41 UTC

Canada's Current Account Deficit Expected to Widen to -5.5 Billion CAD Amid Trade Negotiation Uncertainties with the U.S.

2026. g. 22. aug. 23:41 UTC

Terra is trading lower today, reversing three consecutive sessions of gains. The asset has declined significantly since Friday's close, with no specific news identified.

2026. g. 22. aug. 23:31 UTC

US GDP Price Index QoQ 2nd Estimate on August 26 Forecasts 0.063% Increase Amid Rising Oil Prices and Optimistic Q3 Growth Outlook

2026. g. 22. aug. 23:31 UTC

South Africa's Balance of Trade Data Set for Release Amidst Investor Optimism Following Recent Surplus Growth and Global Economic Pressures.

2026. g. 22. aug. 23:31 UTC

U.S. Home Prices Expected to Rise 1.7% YoY Amid Mixed Economic Sentiment and Market Volatility

2026. g. 22. aug. 23:21 UTC

Market braces for July 2026 PCE Price Index release, with a modest +0.1% increase forecast amid mixed inflation sentiment and external economic pressures.

2026. g. 22. aug. 23:21 UTC

PCE Price Index Release on August 26, 2026: Key Inflation Indicator Amid Market Volatility and Fed Policy Concerns.

2026. g. 22. aug. 23:21 UTC

U.S. Personal Income Expected to Rise 0.3% in August Amid Cautious Market Sentiment and Consumer Spending Concerns

2026. g. 22. aug. 23:21 UTC

U.S. Personal Spending Forecasted to Rise 0.2% in August Amid Mixed Economic Signals and Inflation Concerns

2026. g. 22. aug. 23:21 UTC

Core PCE Price Index MoM for July 2026 set to release on August 26, with a forecasted increase of 0.2%, amid rising oil prices and geopolitical tensions influencing market sentiment.

2026. g. 22. aug. 23:21 UTC

U.S. Durable Goods Orders Ex Transportation Expected to Rise 0.5% Amid Economic Caution and Upcoming Market Influences

2026. g. 22. aug. 23:21 UTC

U.S. Durable Goods Orders Expected to Rise 0.7% Amid Economic Volatility and Geopolitical Tensions, with Market Cautiously Optimistic Ahead of Jackson Hole Symposium

2026. g. 22. aug. 23:21 UTC

U.S. GDP Growth Rate Expected at +1.5% for Q2 2026 Amid Optimistic Economic Indicators and Fed's Revised Forecast of +2.3% for Q3

2026. g. 22. aug. 23:21 UTC

U.S. Corporate Profits Report for Q2 2026 Set to Release Amid Economic Uncertainty and Market Volatility on August 26.

2026. g. 22. aug. 23:11 UTC

ECB Meeting Accounts Set for Release Amid Market Anticipation of Interest Rate Signals and Inflation Trends on August 27, 2026.

2026. g. 22. aug. 23:11 UTC

Mexico's Trade Balance Expected to Show Continued Surplus Amid U.S.-Canada Negotiation Uncertainty Ahead of August 27 Data Release.

2026. g. 22. aug. 23:11 UTC

Brazil's Unemployment Rate Set for Release Amid Optimistic Market Sentiment Following June Drop to 5.4%

2026. g. 22. aug. 23:11 UTC

News

Ethereum is lower today, continuing a decline since Friday's close. Earlier, the asset reached a session low before recovering slightly.

2026. g. 22. aug. 23:11 UTC

Correlated Moves

Avalanche is declining today, influenced by a drop in correlated asset Ethereum. The asset's recent strong performance contrasts with today's downturn during the session.

2026. g. 22. aug. 23:11 UTC

News

Ethereum is lower during Saturday's session, reflecting a significant drop since Friday's close. The asset reached a session low earlier today.

2026. g. 22. aug. 23:01 UTC

Macro News

The DAX 30 Index is declining after the U.S. imposed 50% tariffs on Canadian goods, worsening trade relations and impacting investor sentiment.

Salīdzinājums

Cenas izmaiņa

Zentalis Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

131.15% augšup

Prognoze 12 mēnešiem

Vidējais 8.83 USD  131.15%

Augstākais 11 USD

Zemākais 5 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Zentalis Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

5

Pirkt

1

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Zentalis Pharmaceuticals Inc

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
help-icon Live chat